Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
New UNICEF report highlights urgency of reducing Ebola cases

New UNICEF report highlights urgency of reducing Ebola cases

Ebola has had a devastating impact on children, who make up about 20 per cent of infections in Guinea, Liberia and Sierra Leone. To protect them and their communities, it is critical to defeat this scourge, while working to restore basic services, UNICEF said in a report released today. [More]
Researchers team up to study stomach flu

Researchers team up to study stomach flu

Rice University bioengineers are teaming with colleagues from Baylor College of Medicine and MD Anderson Cancer Center to apply the latest techniques in tissue engineering toward the study of one of the most common and deadly human illnesses -- the stomach flu. [More]
Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects. [More]
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. [More]
The Medical Minute highlights risk and symptoms of IBD in children

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Researchers take images of tiny molecular machine that bacteria use to infect host cells

Researchers take images of tiny molecular machine that bacteria use to infect host cells

Armed with a microscope capable of zooming in on organisms measured in billionths of a meter, scientists report they are the first to observe one of the tiny molecular machines that bacteria use to infect host cells. Findings appear in the Proceedings of the National Academy of Sciences. [More]
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. [More]
Nanobody Nano-85 holds promise for detection of noroviral RNA

Nanobody Nano-85 holds promise for detection of noroviral RNA

Infection with highly contagious noroviruses, while not usually fatal, can lead to a slew of unpleasant symptoms such as excessive vomiting and diarrhea. Current treatment options are limited to rehydration of the patient. "Additionally, noroviruses come in a variety of constantly evolving strains. [More]
FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). [More]
Key questions about colorectal cancer answered

Key questions about colorectal cancer answered

Colorectal cancer is the fourth most common cancer in the U.S., with more than 136,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years. [More]
CEGIR launches patient contact registry for people with eosinophilic gastrointestinal diseases

CEGIR launches patient contact registry for people with eosinophilic gastrointestinal diseases

To coincide with Rare Disease Day 2015, the Consortium of Eosinophilic Gastrointestinal Disease Researchers today launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases. [More]
Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

An aggressive campaign to reduce the unnecessary use of antibiotics has helped cut the rate of infection with a dangerous drug-resistant bacteria at The Valley Hospital by nearly 40 percent. [More]
New initiative aims to provide women in developing countries with access to adequate water sources

New initiative aims to provide women in developing countries with access to adequate water sources

Imagine a day in which your access to clean, drinkable water ceased and you could not shower or bathe properly and you had no one to help you. For more than 783 million people around the world, that day was today. In 2015, more than 2.5 billion people will also lack access to basic sanitation in the developing world. [More]
Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Advertisement